COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Megan H. St. John, Arden R. Barry
openalex +2 more sources
Could Angiotensin Converting Enzyme 2 Inhibitor (ACE2) be the First Line of Defence against SARS-CoV-2 Diseases Covid-19? [PDF]
Daniel Kerr Baines
openalex +1 more source
ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients [PDF]
Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction.
Ewigman, Bernard +2 more
core
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Angiotensin-converting enzyme single nucleotide polymorphism is a genetic risk factor for cardiovascular disease: a cohort study of hypertensive patients [PDF]
Nozomi Kato +6 more
openalex +1 more source
Angiotensin converting enzyme in human seminal plasma is synthesized by the testis, epididymis and prostate [PDF]
Fink, Edwin +4 more
core +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice [PDF]
Mitsuharu Yoshiyama
openalex +1 more source

